• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Deciphering deaths associated with severe serious adverse events following SARS-CoV-2 vaccination: A retrospective cohort study.

作者信息

Ha Jongmok, Song Min Cheol, Park Suyeon, Kang Hyunwook, Kyung Taeeun, Kim Namoh, Kim Dong Kyu, Bae Kihoon, Lee Kwang June, Lee Euiho, Hwang Beom Seuk, Youn Jinyoung, Seok Jin Myoung, Park Kunhee

机构信息

Infectious Disease Control Center, Gyeonggi Provincial Government, Suwon, Korea.

Department of Biostatistics, Soonchunhyang University Seoul Hospital, Seoul, Korea.

出版信息

Vaccine X. 2024 Jan 20;16:100446. doi: 10.1016/j.jvacx.2024.100446. eCollection 2024 Jan.

DOI:10.1016/j.jvacx.2024.100446
PMID:38318232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10839134/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eb7/10839134/9cf1a346fc66/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eb7/10839134/7e85b9ebf6e1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eb7/10839134/f55b34ed56b7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eb7/10839134/9cf1a346fc66/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eb7/10839134/7e85b9ebf6e1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eb7/10839134/f55b34ed56b7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eb7/10839134/9cf1a346fc66/gr3.jpg

相似文献

1
Deciphering deaths associated with severe serious adverse events following SARS-CoV-2 vaccination: A retrospective cohort study.解读与新型冠状病毒2疫苗接种后严重不良事件相关的死亡：一项回顾性队列研究。
Vaccine X. 2024 Jan 20;16:100446. doi: 10.1016/j.jvacx.2024.100446. eCollection 2024 Jan.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on.美国接种 SARS-CoV-2 疫苗后报告的严重不良事件分析：一年后。
Front Public Health. 2022 Oct 13;10:972464. doi: 10.3389/fpubh.2022.972464. eCollection 2022.
4
Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.美国成年人中，既往感染 SARS-CoV-2 与 mRNA COVID-19 疫苗接种后严重全身不良事件的相关性。
Vaccine. 2022 Dec 12;40(52):7653-7659. doi: 10.1016/j.vaccine.2022.10.073. Epub 2022 Nov 1.
5
Adverse Events Following One Dose of mRNA COVID-19 Vaccination Among US Nursing Home Residents With and Without a Previous SARS-CoV-2 Infection.美国有和没有既往 SARS-CoV-2 感染的养老院居民接种一剂 mRNA COVID-19 疫苗后的不良事件。
J Am Med Dir Assoc. 2021 Nov;22(11):2228-2232. doi: 10.1016/j.jamda.2021.08.024. Epub 2021 Aug 28.
6
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.≥65 岁成年人中同时接种高剂量四价流感疫苗和 mRNA-1273 新冠疫苗第三针的安全性和免疫原性：一项 2 期、随机、开放标签研究。
Lancet Respir Med. 2022 Apr;10(4):392-402. doi: 10.1016/S2213-2600(21)00557-9. Epub 2022 Feb 1.
7
A retrospective cohort study: vaccination status and safety analysis of SARS-CoV-2 vaccine in patients with Wilson's disease.一项回顾性队列研究：Wilson 病患者 SARS-CoV-2 疫苗接种状况及安全性分析。
Expert Rev Vaccines. 2023 Jan-Dec;22(1):1185-1195. doi: 10.1080/14760584.2023.2288630. Epub 2023 Dec 1.
8
Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.墨西哥接种疫苗后，德尔塔和奥密克戎 SARS-CoV-2 波期间成年人 COVID-19 不良结局减少。
Front Public Health. 2022 Sep 13;10:1010256. doi: 10.3389/fpubh.2022.1010256. eCollection 2022.
9
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
10
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.mRNA-1273 新冠病毒疫苗在接受化疗、免疫疗法或化疗免疫疗法治疗实体瘤的患者中的应用：一项前瞻性、多中心、非劣效性试验。
Lancet Oncol. 2021 Dec;22(12):1681-1691. doi: 10.1016/S1470-2045(21)00574-X. Epub 2021 Nov 9.

引用本文的文献

1
Mortality in severe serious adverse events following heterologous and homologous prime-boost vaccination strategies for SARS-CoV-2: A retrospective cohort study.SARS-CoV-2异源和同源加强免疫接种策略后严重不良事件的死亡率：一项回顾性队列研究。
PLoS One. 2025 May 23;20(5):e0323736. doi: 10.1371/journal.pone.0323736. eCollection 2025.
2
Serious adverse events following immunization and predictors of mortality associated with COVID-19 vaccination in India: a secondary data analysis of nationwide causality assessments.印度新冠疫苗接种后的严重不良事件及与新冠疫苗接种相关的死亡预测因素：全国因果关系评估的二次数据分析
Ther Adv Vaccines Immunother. 2025 Mar 2;13:25151355251321697. doi: 10.1177/25151355251321697. eCollection 2025.

本文引用的文献

1
Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination.了解新冠病毒疫苗接种后伴有血小板减少的血栓形成综合征
NPJ Vaccines. 2022 Nov 9;7(1):141. doi: 10.1038/s41541-022-00569-8.
2
Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study.意大利博洛尼亚的 COVID-19 疫苗接种后短期死亡率：一项为期一年的研究。
Vaccine. 2022 Sep 16;40(39):5709-5715. doi: 10.1016/j.vaccine.2022.08.039. Epub 2022 Aug 22.
3
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens.
异源 ChAdOx1-nCoV-19 初免和 BNT162b2 或 mRNA-1273 加强与同源 COVID-19 疫苗方案的免疫原性和反应原性比较。
Nat Commun. 2022 Aug 11;13(1):4710. doi: 10.1038/s41467-022-32321-0.
4
Impact of age, sex, race, and regionality on major clinical outcomes of COVID-19 in hospitalized patients in the United States.年龄、性别、种族和地域对美国住院 COVID-19 患者主要临床结局的影响。
BMC Infect Dis. 2022 Jul 29;22(1):659. doi: 10.1186/s12879-022-07611-z.
5
Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines.新冠信使 RNA 疫苗接种后心肌炎和心包炎的年龄和性别特异性风险。
Nat Commun. 2022 Jun 25;13(1):3633. doi: 10.1038/s41467-022-31401-5.
6
Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.香港接种 mRNA（BNT162b2）和灭活（科兴）SARS-CoV-2 疫苗后特殊关注的不良事件和死亡率：一项回顾性研究。
PLoS Med. 2022 Jun 21;19(6):e1004018. doi: 10.1371/journal.pmed.1004018. eCollection 2022 Jun.
7
Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis.COVID-19 mRNA 疫苗的不良反应：刺突假说。
Trends Mol Med. 2022 Jul;28(7):542-554. doi: 10.1016/j.molmed.2022.04.007. Epub 2022 Apr 21.
8
Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated?欧洲药品管理局（EMA）批准的新冠疫苗接种后的死亡情况：是否已证实存在因果关系？
Vaccines (Basel). 2022 Feb 16;10(2):308. doi: 10.3390/vaccines10020308.
9
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines.针对基于蛋白质、信使核糖核酸和载体的新冠疫苗，对严重急性呼吸综合征冠状病毒2中和抗体水平进行的校准比较。
NPJ Vaccines. 2022 Feb 18;7(1):22. doi: 10.1038/s41541-022-00455-3.
10
COVID-19 vaccination program in South Korea: A long journey toward a new normal.韩国的新冠疫苗接种计划：迈向新常态的漫长征程。
Health Policy Technol. 2022 Jun;11(2):100601. doi: 10.1016/j.hlpt.2022.100601. Epub 2022 Jan 31.